Cebranopadol reduced pain intensity in patients following abdominoplasty surgery in the ALLEVIATE-1 clinical trial.
The following is a summary of “Repetitive Transcranial Magnetic Stimulation for the Treatment of Complex Regional Pain Syndrome: A Pilot Study,” published in the January 2025 issue of Pain by Foglia ...
The following is a summary of “Pain Assessment and Management in Oncological Practice: A Survey from the Italian Network of ...
The new data comes from the phase 3 ALLEVIATE-1 trial, which compared cebranopadol to placebo for the management of ...
GlobalData on MSN3d
Tris Pharma reports positive data from Phase III acute pain therapy trialTris Pharma has reported positive topline outcomes from its ALLEVIATE-1 Phase III trial of cebranopadol for treating moderate ...
Physician empathy has long been recommended — but not required — in the doctor-patient relationship.However, for a growing ...
ZME Science on MSN2d
Researchers made an AI feel pain, because what could go wrong?What could possibly go wrong with giving machines a taste of suffering? It's not like they'd take over the world or something ...
In phase 3 testing, the drug achieved around 50% reduction in the numeric pain rating scale used to measure pain intensity ...
Further endpoints included improvements in back pain (Numeric Rating Scale [NRS] scores), spinal stiffness, functional ...
GlobalData on MSN10d
Mainstay Medical study demonstrates benefit of neurostimulation for back painThe company’s one-year study demonstrated the superiority of the ReActiv8 system for treating chronic low back pain over the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback